Industry Briefs: June 25, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Bristol-Myers Squibb and Pfizer have received a Complete Response Letter from FDA for Eliquis (apixaban), for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Impax Laboratories and Tolmar have entered into a multiproduct agreement for the development, supply, and distribution of generic topical prescription drug products.
FDA has issued Janssen R&D a Complete Response Letter for Xarelto (rivaroxaban) for the reduction of secondary cardiovascular events in patients with acute coronary syndrome
PharmaNet/i3 has launched PharmaNet/i3 Strategic Resourcing, a new provider of staffing and functional service provider services.
Quotient Clinical and Capsugel have announced a collaboration for the development and clinical assessment of lipid-based formulations.
Takeda North America has changed its name to Takeda Pharmaceuticals USA.
WIL Research Company has selected Thermo Fisher Scientific’s Q Exactive mass spectrometer systems to expand its capabilities for regulated bioanalysis, drug discovery, metabolism, and structural identification services.
People News
Takeda has announced a new assignment of directors, the appointment of corporate officers and a change of senior leadership. Key appointments include Masato Iwasaki as director and senior vice-president of Pharmaceutical Marketing, and Deborah Dunsire as director, president, and CEO of the company’s subsidiary Millennium Pharmaceuticals.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
